Abstract
P166 Budget impact of MammaPrint® in Patients with primary hormone receptor-positive, HER2-negative and non-metastatic early-stage breast cancer in France
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
